Tuesday - June 9, 2026
Boehringer Ingelheim's Survodutide Phase III Trial Showed Targeted 34% Visceral and 63% Liver Fat Reduction, While Minimizing Lean Mass Loss in Pre-specified Analysis, Supporting Improved Metabolic Health in People Living With Obesity
June 09, 2026
INGELHEIM AM RHEIN, Germany, June 9 (TNSxrep) -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release on June 7, 2026:

* * *

Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

* News builds on previously announced positive topline result . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products